Widely regarded as a leading expert regarding the off-label use of etanercept as a neurology therapeutic, Dr. Edward Tobinick stands out as the founder of the Institute of Neurological Recovery. There, he leads a team of physicians in developing innovative treatments for stroke, sciatica, and other serious conditions. Dr. Edward Tobinick and his team study such paradigm-shifting concepts as the effect of immune mechanisms on neuroinflammatory conditions, a research thread that has in turn led to numerous discoveries regarding the processes of tumor necrosis factor (TNF) and TNF blockers with respect to neuroinflammation.
A reviewer for such journals as Experimental Neurology and the Journal of Neurochemistry, Dr. Edward Tobinick is also a former member of the editorial board for the Journal of Neuroinflammation. He has received scientific citations in hundreds of scientific publications and has published articles in a variety of neurology, neuroscience, and other specialty journals. Dr. Tobinick has also secured more than 20 U.S. patents for his treatment innovations, such as a molecule delivery system that facilitates the passage of certain therapeutic agents across the blood-cerebrospinal fluid barrier. A diplomate of the American Board of Internal Medicine and the American Board of Dermatology, he leads research and physician training efforts at the Institute of Neurological Recovery.